Pulmonary artery pressure and iron deficiency in patients with upregulation of hypoxia sensing due to homozygous VHLR200W mutation (Chuvash polycythemia)

Background Patients with Chuvash polycythemia, (homozygosity for the R200W mutation in the von Hippel Lindau gene (VHL)), have elevated levels of hypoxia inducible factors HIF-1 and HIF-2, often become iron-deficient secondary to phlebotomy, and have elevated estimated pulmonary artery pressure by echocardiography. The objectives of this study were to provide a comprehensive echocardiographic assessment of cardiovascular physiology and to identify clinical, hematologic and cardiovascular risk factors for elevation of tricuspid regurgitation velocity in children and adults with Chuvash polycythemia. Design and Methods This cross-sectional observational study of 120 adult and pediatric VHLR200W homozygotes and 31 controls at outpatient facilities in Chuvashia, Russian Federation included echocardiography assessment of pulmonary artery pressure (tricuspid regurgitation velocity), cardiac volume, and systolic and diastolic function, as well as hematologic and clinical parameters. We determined the prevalence and risk factors for elevation of tricuspid regurgitation velocity in this population and its relationship to phlebotomy. Results The age-adjusted mean ± SE tricuspid regurgitation velocity was higher in VHLR200W homozygotes than controls with normal VHL alleles (2.5±0.03 vs. 2.3±0.05 m/sec, P=0.005). The age-adjusted left ventricular diastolic diameter (4.8±0.05 vs. 4.5±0.09 cm, P=0.005) and left atrial diameter (3.4±0.04 vs. 3.2±0.08 cm, P=0.011) were also greater in the VHLR200W homozygotes, consistent with increased blood volume, but the elevation in tricuspid regurgitation velocity persisted after adjustment for these variables. Among VHLR200W homozygotes, phlebotomy therapy was associated with lower serum ferritin concentration, and low ferritin independently predicted higher tricuspid regurgitation velocity (standardized beta=0.29; P=0.009). Conclusions Children and adults with Chuvash polycythemia have higher estimated right ventricular systolic pressure, even after adjustment for echocardiography estimates of blood volume. Lower ferritin concentration, which is associated with phlebotomy, independently predicts higher tricuspid regurgitation velocity (www.clinicaltrials.gov identifier NCT00495638).

[1]  E. Tay,et al.  Replacement therapy for iron deficiency improves exercise capacity and quality of life in patients with cyanotic congenital heart disease and/or the Eisenmenger syndrome. , 2011, International Journal of Cardiology.

[2]  J. Wharton,et al.  Iron deficiency and raised hepcidin in idiopathic pulmonary arterial hypertension: clinical prevalence, outcomes, and mechanistic insights. , 2011, Journal of the American College of Cardiology.

[3]  Thomas G. Smith,et al.  Cardiopulmonary function in two human disorders of the hypoxia-inducible factor (HIF) pathway: von Hippel-Lindau disease and HIF-2α gain-of-function mutation , 2011, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[4]  N. Morrell,et al.  Unexplained iron deficiency in idiopathic and heritable pulmonary arterial hypertension , 2011, Thorax.

[5]  N. Westerhof,et al.  Iron deficiency is common in idiopathic pulmonary arterial hypertension , 2010, European Respiratory Journal.

[6]  E. Vichinsky,et al.  Pulmonary hypertension in thalassemia , 2010, Annals of the New York Academy of Sciences.

[7]  W. Kaelin,et al.  Reactivation of Hepatic EPO Synthesis in Mice After PHD Loss , 2010, Science.

[8]  M. Gladwin,et al.  Effect of eculizumab on haemolysis‐associated nitric oxide depletion, dyspnoea, and measures of pulmonary hypertension in patients with paroxysmal nocturnal haemoglobinuria , 2010, British journal of haematology.

[9]  E. Morrisey,et al.  The von Hippel-Lindau Chuvash mutation promotes pulmonary hypertension and fibrosis in mice. , 2010, The Journal of clinical investigation.

[10]  G. Kato,et al.  Pleiotropic effects of intravascular haemolysis on vascular homeostasis , 2010, British journal of haematology.

[11]  M. Gladwin,et al.  Angiogenic and Inflammatory Markers of Cardiopulmonary Changes in Children and Adolescents with Sickle Cell Disease , 2009, PloS one.

[12]  Thomas G. Smith,et al.  Effects of iron supplementation and depletion on hypoxic pulmonary hypertension: two randomized controlled trials. , 2009, JAMA.

[13]  Ge Rili,et al.  Changes of Cardiac Structure and Function in Pediatric Patients with High Altitude Pulmonary Hypertension in Tibet , 2009 .

[14]  M. Gladwin,et al.  Prospective echocardiography assessment of pulmonary hypertension and its potential etiologies in children with sickle cell disease. , 2009, The American journal of cardiology.

[15]  R. Rodeheffer,et al.  Age-Associated Increases in Pulmonary Artery Systolic Pressure in the General Population , 2009, Circulation.

[16]  G. Semenza.  Regulation of oxygen homeostasis by hypoxia-inducible factor 1. , 2009, Physiology.

[17]  M. Gladwin,et al.  Elevated tricuspid regurgitant jet velocity in children and adolescents with sickle cell disease: association with hemolysis and hemoglobin oxygen desaturation , 2008, Haematologica.

[18]  Thomas G. Smith,et al.  The increase in pulmonary arterial pressure caused by hypoxia depends on iron status , 2008, The Journal of physiology.

[19]  Wei Du,et al.  Regression equations for calculation of z scores of cardiac structures in a large cohort of healthy infants, children, and adolescents: an echocardiographic study. , 2008, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

[20]  W. Kaelin,et al.  Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway. , 2008, Molecular cell.

[21]  Kai-Uwe Eckardt,et al.  Epidermal Sensing of Oxygen Is Essential for Systemic Hypoxic Response , 2008, Cell.

[22]  Yong J. Lee,et al.  Flavonoids‐induced accumulation of hypoxia‐inducible factor (HIF)‐1α/2α is mediated through chelation of iron , 2008 .

[23]  F. Pashankar,et al.  Prevalence and Risk Factors of Elevated Pulmonary Artery Pressures in Children With Sickle Cell Disease , 2008, Pediatrics.

[24]  M. McMullin,et al.  A gain-of-function mutation in the HIF2A gene in familial erythrocytosis. , 2008, The New England journal of medicine.

[25]  W. Rathmell,et al.  von Hippel-Lindau mutation in mice recapitulates Chuvash polycythemia via hypoxia-inducible factor-2alpha signaling and splenic erythropoiesis. , 2007, The Journal of clinical investigation.

[26]  Mayka Sanchez,et al.  Iron-regulatory proteins limit hypoxia-inducible factor-2α expression in iron deficiency , 2007, Nature Structural &Molecular Biology.

[27]  J. Rychik,et al.  Guidelines and standards for performance of a pediatric echocardiogram: a report from the Task Force of the Pediatric Council of the American Society of Echocardiography. , 2006, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

[28]  J. Prchal,et al.  Vascular complications in Chuvash polycythemia. , 2006, Seminars in thrombosis and hemostasis.

[29]  G. Semenza.  Involvement of hypoxia-inducible factor 1 in pulmonary pathophysiology. , 2005, Chest.

[30]  M. Gladwin,et al.  Diastolic dysfunction is an independent risk factor for death in patients with sickle cell disease. , 2005, Journal of the American College of Cardiology.

[31]  J. Krishnan,et al.  Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. , 2004, The New England journal of medicine.

[32]  P. Choyke,et al.  Congenital disorder of oxygen sensing: association of the homozygous Chuvash polycythemia VHL mutation with thrombosis and vascular abnormalities but not tumors. , 2004, Blood.

[33]  P. Carmeliet,et al.  Heterozygous deficiency of hypoxia-inducible factor-2alpha protects mice against pulmonary hypertension and right ventricular dysfunction during prolonged hypoxia. , 2003, The Journal of clinical investigation.

[34]  W. Kaelin,et al.  HIF hydroxylation and the mammalian oxygen-sensing pathway. , 2003, The Journal of clinical investigation.

[35]  David Mole,et al.  Disruption of oxygen homeostasis underlies congenital Chuvash polycythemia , 2002, Nature Genetics.

[36]  P. Sutphin,et al.  Role of Prolyl Hydroxylation in Oncogenically Stabilized Hypoxia-inducible Factor-1α* , 2002, The Journal of Biological Chemistry.

[37]  T. Kuriyama,et al.  Effects of Hemoglobin on Pulmonary Arterial Pressure and Pulmonary Vascular Resistance in Patients with Chronic Emphysema , 2000, Respiration.

[38]  M. Rubenfire,et al.  Range of tricuspid regurgitation velocity at rest and during exercise in normal adult men: implications for the diagnosis of pulmonary hypertension. , 1999, Journal of the American College of Cardiology.

[39]  M. Quiñones,et al.  Doppler tissue imaging: a noninvasive technique for evaluation of left ventricular relaxation and estimation of filling pressures. , 1997, Journal of the American College of Cardiology.

[40]  A. Van Tosh,et al.  Quantitative assessment of pulmonary hypertension in patients with tricuspid regurgitation using continuous wave Doppler ultrasound. , 1985, Journal of the American College of Cardiology.

[41]  R. Ge,et al.  Changes of cardiac structure and function in pediatric patients with high altitude pulmonary hypertension in Tibet. , 2009, High altitude medicine & biology.

[42]  Yong J. Lee,et al.  Flavonoids-induced accumulation of hypoxia-inducible factor (HIF)-1alpha/2alpha is mediated through chelation of iron. , 2008, Journal of cellular biochemistry.

[43]  P. Robbins,et al.  Mutation of the von Hippel-Lindau gene alters human cardiopulmonary physiology. , 2008, Advances in experimental medicine and biology.

[44]  S. Nekhai,et al.  Endothelin-1, vascular endothelial growth factor and systolic pulmonary artery pressure in patients with Chuvash polycythemia. , 2006, Haematologica.

[45]  J. Reeves,et al.  Insights by Peruvian scientists into the pathogenesis of human chronic hypoxic pulmonary hypertension. , 2005, Journal of applied physiology.

[46]  American Society of Echocardiography , 2022 .

[47]  Thomas G. Smith,et al.  Competing Interests: PHM, CWP, , 2022 .